Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
BMY trades against a final fair-value range of $68.85-$100.89, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Bristol-Myers Squibb is facing a massive loss of exclusivity wave. A failure in executing its new product launches would transform its 9.1x distressed multiple into a value trap, threatening the sustainability of its 70% dividend payout.
New assets like Opdualag and Camzyos completely fail to offset the multi-billion-dollar revenue crater from the Revlimid and Eliquis patent cliff.
Regulatory and pricing pressures under the Inflation Reduction Act permanently compress operating margins well below the projected 29%.
Management pursues aggressively overpriced acquisitions to patch the pipeline gap, significantly destroying ROIC and elevating debt.
| Pozycja | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Przychody | $46.16B | $45.01B-2.5% | $48.30B+7.3% | $48.20B-0.2% | +1.4% |
| Zysk brutto | $36.02B | $34.31B | $34.33B | $34.26B | -1.7% |
| Zysk operacyjny | $9.10B | $8.20B | $5.89B | $13.72B | +14.7% |
| Zysk netto | $6.33B | $8.03B+26.9% | $-8.95B | $7.05B | +3.7% |
| EPS (rozwodniony) | $2.95 | $3.86 | $-4.41 | $3.46 | +5.5% |
| EBITDA | $19.22B | $19.37B | $3.17B | $15.23B | -7.5% |
| R&D | $9.51B | $9.30B | $11.16B | $9.95B | +1.5% |
| SG&A | $7.81B | $7.77B | $8.41B | $7.27B | -2.4% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
